At the end of this presentation, participants should be better able to:

• Describe the neuropharmacology and pharmacokinetics of synthetic cannabinoids and fentanyl analogs’ addictive potential.
• Identify differences between various synthetic cannabinoids and fentanyl analog products.
• Review the prevalence statistics for synthetic cannabinoids and fentanyl analogs among commonly abused substances.
• Review the current state of detection methodologies to detect synthetic cannabinoids and fentanyl analogs.
• Review harm reduction technologies and overdose treatments for these agents.